Wellington Shields Capital Management LLC Trims Holdings in Johnson & Johnson $JNJ

Key Points

• Wellington Shields Capital Management cut its Johnson & Johnson stake by 29.4% in the second quarter, selling 5,241 shares and retaining 12,573 shares valued at approximately $3.19 million. Institutional investors and hedge funds own 69.55% of JNJ.
• Johnson & Johnson reported quarterly EPS of $2.90 and revenue of $25.31 billion, exceeding analyst expectations, while revenue rose 6.6% year over year. The company declared a quarterly dividend of $1.34, or $5.36 annualized, representing a 2.0% yield.
• JNJ shares opened at $271.53, near their 52-week high of $276.47. Analysts maintain a consensus “Moderate Buy” rating with an average price target of $268.22, despite mixed target revisions and one recent downgrade to “Hold.”

Wellington Shields Capital Management LLC lessened its stake in Johnson & Johnson (NYSE:JNJ - Free Report) by 29.4% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 12,573 shares of the company's stock after selling 5,241 shares during the period. Wellington Shields Capital Management LLC's holdings in Johnson & Johnson were worth $3,193,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in JNJ. Blueline Advisors LLC acquired a new position in Johnson & Johnson during the 4th quarter worth $25,000. Cresta Advisors Ltd. acquired a new stake in shares of Johnson & Johnson in the 4th quarter valued at about $26,000. Bay Harbor Wealth Management LLC lifted its position in shares of Johnson & Johnson by 49.0% during the fourth quarter. Bay Harbor Wealth Management LLC now owns 149 shares of the company's stock worth $31,000 after purchasing an additional 49 shares during the last quarter. Matrix Trust Co grew its stake in Johnson & Johnson by 56.2% in the second quarter. Matrix Trust Co now owns 150 shares of the company's stock worth $38,000 after purchasing an additional 54 shares in the last quarter. Finally, E Fund Management Hong Kong Co. Ltd. grew its stake in Johnson & Johnson by 946.7% in the fourth quarter. E Fund Management Hong Kong Co. Ltd. now owns 157 shares of the company's stock worth $32,000 after purchasing an additional 142 shares in the last quarter. 69.55% of the stock is owned by institutional investors and hedge funds.

More Johnson & Johnson News

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Defensive strength supported the stock. JNJ gained as the broader market weakened, suggesting investors favored its relatively stable healthcare business and dependable dividend. The company has maintained a decades-long dividend-growth streak, making it attractive to income-oriented investors. Johnson & Johnson (JNJ) Rises As Market Takes a Dip: Key Facts
• Positive Sentiment: Upcoming results provide a potential catalyst. Johnson & Johnson will host its third-quarter earnings conference call on October 13. Investors will focus on operating trends, guidance and updates on key risks. Johnson & Johnson to Host Investor Conference Call on Third-Quarter Results
• Neutral Sentiment: J&J’s investment portfolio received favorable attention. The company owns stakes in approximately 15 biotechnology and medical-technology companies, with one larger holding standing out because of its market capitalization. The portfolio may offer strategic or financial upside, but it is not currently a major earnings catalyst. Johnson & Johnson Owns Stakes in 15 Stocks. Here's the Best of the Bunch.
• Negative Sentiment: One analyst modestly reduced its earnings forecast. Erste Group Bank lowered its 2026 EPS estimate to $11.65 from $11.68, although the revised forecast remains above the broader consensus estimate of $11.61. The small cut is a mild negative signal rather than a material change to the outlook.
• Negative Sentiment: Dividend investors face a longer-term uncertainty. Commentary comparing JNJ with Procter & Gamble highlights a forthcoming corporate event that could threaten the uninterrupted payout record investors associate with J&J. The article does not indicate an immediate dividend reduction, but the issue may temper enthusiasm among income-focused shareholders. Why Procter & Gamble’s Quieter Dividend Outpaces Johnson & Johnson’s Growth Story

Analysts Set New Price Targets

JNJ has been the topic of several research reports. Wall Street Zen cut Johnson & Johnson from a "buy" rating to a "hold" rating in a research note on Saturday, August 1st. Argus set a $300.00 target price on Johnson & Johnson in a research report on Wednesday, July 29th. Citigroup boosted their price target on Johnson & Johnson from $285.00 to $298.00 and gave the company a "buy" rating in a report on Wednesday, July 8th. Wells Fargo & Company upped their price target on Johnson & Johnson from $272.00 to $282.00 and gave the company an "overweight" rating in a research report on Monday, August 3rd. Finally, Bank of America raised their price objective on Johnson & Johnson from $254.00 to $263.00 and gave the stock a "neutral" rating in a research note on Friday, July 10th. One analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and six have given a Hold rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $268.22.

Johnson & Johnson Stock Up 2.1%

JNJ stock opened at $271.53 on Wednesday. The stock has a market cap of $654.36 billion, a PE ratio of 31.46, a price-to-earnings-growth ratio of 2.54 and a beta of 0.24. The firm's 50-day simple moving average is $260.21 and its 200 day simple moving average is $244.39. Johnson & Johnson has a fifty-two week low of $173.33 and a fifty-two week high of $276.47. The company has a quick ratio of 0.81, a current ratio of 1.09 and a debt-to-equity ratio of 0.44.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its earnings results on Wednesday, July 15th. The company reported $2.90 EPS for the quarter, topping the consensus estimate of $2.84 by $0.06. Johnson & Johnson had a net margin of 21.48% and a return on equity of 32.42%. The firm had revenue of $25.31 billion during the quarter, compared to analysts' expectations of $25.06 billion. During the same quarter in the prior year, the firm earned $2.77 EPS. Johnson & Johnson's quarterly revenue was up 6.6% on a year-over-year basis. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. As a group, sell-side analysts predict that Johnson & Johnson will post 11.61 EPS for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 8th. Investors of record on Tuesday, August 25th will be issued a $1.34 dividend. This represents a $5.36 dividend on an annualized basis and a yield of 2.0%. The ex-dividend date of this dividend is Tuesday, August 25th. Johnson & Johnson's dividend payout ratio is 62.11%.

Insiders Place Their Bets

In other Johnson & Johnson news, EVP Kathryn E. Wengel sold 10,000 shares of the business's stock in a transaction on Thursday, June 11th. The stock was sold at an average price of $241.15, for a total transaction of $2,411,500.00. Following the completion of the transaction, the executive vice president owned 114,288 shares in the company, valued at approximately $27,560,551.20. The trade was a 8.05% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Vanessa Broadhurst sold 23,054 shares of the stock in a transaction on Monday, July 20th. The stock was sold at an average price of $251.27, for a total value of $5,792,778.58. Following the completion of the transaction, the executive vice president directly owned 23,003 shares of the company's stock, valued at approximately $5,779,963.81. The trade was a 50.06% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 63,972 shares of company stock valued at $16,245,605. 0.16% of the stock is owned by corporate insiders.

About Johnson & Johnson

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company's pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source